MedTrace Logo

Ivermectin Treatment Efficacy in Covid-19 High Risk Patients

NCT04920942 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2023-06-01

No results posted yet for this study

Summary

This is a multicenter study, which is aimed to investigate the efficacy of the Ivermectin drug in high risk COVID-19 patients. This study will compare Ivermectin treatment efficacy with standard of care alone. Target cohort is mild to moderate symptomatic Covid-19 (Stage 2-3), high risk patients aged 50 years and above with comorbidity, who presented to hospitals within first 7 days of illness.

Conditions

Interventions

DRUG

Ivermectin 0.4mg/kg/day for 5 days

Ivermectin 0.4mg/kg/day for 5 days with standard-of-care

Sponsors & Collaborators

  • Clinical Research Centre, Malaysia

    lead OTHER

Principal Investigators

  • CHEE L LIM, MRCP · Ministry of Health, Malaysia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-31
Primary Completion
2021-10-31
Completion
2021-10-31

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04920942 on ClinicalTrials.gov